Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study

Berenice Anabel Silva, Esteban Miglietta, Juan Cruz Casabona, Shirley D. Wenker, María Bárbara Eizaguirre, Ricardo Alonso, Magdalena Casas, Luciana Grimanesa Lázaro, Federico Man, Gustavo Portuondo, Abril Lopez Bisso, Noelia Zavala, Federico Casales, Gastón Imhoff, Dra Judith Steinberg, Pablo A. López, Edgar Carnero Contentti, Norma Deri, Vladimiro Sinay, Javier Hryb, Edson Chiganer, Felisa Leguizamón, Verónica Tkachuk, Johana Bauer, Flavia Ferrandina, Susana Giachello, Paula Henestroza, Orlando Garcea, Carla A. Pascuale, Mauro Heitrich, Osvaldo L. Podhajcer, Sabrina E. Vinzón, Tomás Dalotto‐Moreno, Alejandro Benatar, Gabriel A. Rabinovich, Fernando J. Pitossi, Carina Cintia FerrariFrontiers in Immunology 2024 · DOI

Abstract

Findings regarding humoral and cellular response are consistent with previous reports, indicating that while certain Multiple Sclerosis (MS) treatments impair antibody production following adenovirus-based vaccination, cellular immunity often remains intact.

Introduction

While extensive data exists regarding mRNA-based COVID-19 vaccines (like Pfizer or Moderna), a significant knowledge gap remains concerning adenovirus-based platforms such as Sputnik V and AstraZeneca (AZD1222). These vaccines were cornerstones of the pandemic response in Latin America. This study investigates how Disease-Modifying Therapies (DMTs) used in MS affect the immune response to these specific vaccine vectors, particularly against emerging variants like Omicron.

Methods

Researchers conducted a prospective, longitudinal study in Argentina involving 101 patients with MS (pwMS) and 28 healthy controls (HC). The pwMS were grouped by their specific DMT: fingolimod, dimethyl fumarate (DMF), cladribine, or anti-CD20 therapies (ocrelizumab/rituximab).

Experimental workflow for assessing humoral and cellular immune responses post-vaccination.

Key technical approaches included measuring IgG antibodies against the SARS-CoV-2 spike protein (COVIDAR platform), neutralization assays against the Wuhan and Omicron variants, and flow cytometry to analyze T-cell activation (CD4+ and CD8+ cells) after stimulating peripheral blood mononuclear cells with viral peptides.

Key Results

The study revealed that treatment type significantly influences seroconversion rates. After two doses, 100% of patients on DMF and Cladribine produced antibodies, compared to only 57.8% on fingolimod and a mere 26.4% on anti-CD20 therapies.

Comparison of COVIDAR IgG antibody titers across different disease-modifying therapies.

Multivariate regression identified anti-CD20 ($p=0.017$) and fingolimod ($p=0.023$) as independent factors associated with low antibody response. Furthermore, for patients on anti-CD20, antibody titers were higher when the interval between the drug infusion and vaccination was longer ($r=0.49, p=0.03$).

Discussion: The T-Cell Safety Net and Booster Efficacy

Perhaps the most encouraging finding was the preservation of cellular immunity. Patients on anti-CD20 therapies—who often failed to produce detectable antibodies—still generated robust CD8+ T-cell responses comparable to healthy controls. This suggests that even if the antibody response is impaired, the body's cellular "internal security" can still recognize and fight the virus.

Additionally, the third vaccine dose proved vital. For some previous non-responders (particularly those on fingolimod), the third dose triggered seroconversion. While neutralization capacity against Omicron was lower than against the original Wuhan strain across all groups, the third dose significantly narrowed this gap, reinforcing the necessity of boosters for immunocompromised populations.

Limitations and Future Work

The authors acknowledge limitations including a relatively small sample size in some DMT subgroups and the lack of baseline antibody data prior to the first vaccine dose. Future research should focus on whether adjusting the timing of DMT infusions can further optimize the window for vaccination without increasing the risk of MS relapses.

Summary updated

Abstract

Findings regarding humoral and cellular response are consistent with previous reports.
BibTeX
@inproceedings{silva2024do,
  author = {Berenice Anabel Silva and Esteban Miglietta and Juan Cruz Casabona and Shirley D. Wenker and María Bárbara Eizaguirre and Ricardo Alonso and Magdalena Casas and Luciana Grimanesa Lázaro and Federico Man and Gustavo Portuondo and Abril Lopez Bisso and Noelia Zavala and Federico Casales and Gastón Imhoff and Dra Judith Steinberg and Pablo A. López and Edgar Carnero Contentti and Norma Deri and Vladimiro Sinay and Javier Hryb and Edson Chiganer and Felisa Leguizamón and Verónica Tkachuk and Johana Bauer and Flavia Ferrandina and Susana Giachello and Paula Henestroza and Orlando Garcea and Carla A. Pascuale and Mauro Heitrich and Osvaldo L. Podhajcer and Sabrina E. Vinzón and Tomás Dalotto‐Moreno and Alejandro Benatar and Gabriel A. Rabinovich and Fernando J. Pitossi and Carina Cintia Ferrari},
  title = {{Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1431403},
}
Figure